Description of the medicine: Flumazenil (Flumazenil)
Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a] [1,4] benzodiazepine-3-carboxylate.
Synonym: Anexat, Anexate.
White or almost white crystalline powder. Insoluble in water, slightly soluble in acidic aqueous solutions.
Being a competitive blocker of benzodiazepine receptors, it eliminates the central psychomotor effects of benzodiazepine tranquilizers: it neutralizes hypnotic sedative effect, helps to restore breathing and consciousness in case of overdose. At the same time, it has an internal agonistic activity with respect to benzodiazepine receptors and has an anticonvulsant effect.
It is used to eliminate the central (except for anticonvulsant) effects of benzodiazepine tranquilizers (including when removing from anesthesia, differential diagnosis of their overdose).
Assign intravenously (in a 5% glucose solution or 0.9% sodium chloride solution): in anesthetic practice - 0.0002 g (0.2 mg) for 15 s, if necessary 0.0001 (0.1 mg) through 1 min to a total dose of 0.001 g (1 mg); in intensive care - in an initial dose of 0,0003 g (0.3 mg); if necessary, repeatedly every 60 s to a total dose of 0.002 g (2 mg).
Possible side effects: flushing, fear, palpitations (with rapid administration), cramps (with a history of epilepsy), symptoms of benzodiazepine withdrawal.
Release form: 0.01% solution for injection in ampoules of 5 and 10 ml.
Storage: List B.